Incretin Atlas › Trials › TRANSCEND-T2D-2 (vs semaglutide 2 mg)
TRANSCEND-T2D-2 (vs semaglutide 2 mg)
Retatrutide · t2d
Design
- Molecule(s)
- Retatrutide
- Population
- t2d
- Official title
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- active not recruiting · 2024-02 → 2026-08
- Participants
- 1250
- Duration
- 80 weeks
- Registry
- NCT06260722
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| retatrutide 9 mg vs semaglutide 2 mg (active) | t2d | 80 | — | −19.5 % | — | −2.2 | 4.8 | — | 21.2 | 10.2 | — | — | press release |
| retatrutide 12 mg vs semaglutide 2 mg (active) | t2d | 80 | — | −20.9 % | — | −2.2 | 7.9 | — | 23.8 | 15.0 | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- retatrutide 9 mg: Head-to-head, open-label, vs semaglutide 2 mg: weight −9.4 %, HbA1c −1.8 %-points (efficacy estimand); AE discontinuation 2.7 %, nausea 21.3 %, vomiting 13.2 %. N=1,298 randomised 2:2:1; primary endpoint HbA1c non-inferiority of 12 mg; HbA1c superiority of 9 mg nominal only. Topline release; publication pending.
- retatrutide 12 mg: Head-to-head, open-label, vs semaglutide 2 mg: weight −9.4 %, HbA1c −1.8 %-points (efficacy estimand); AE discontinuation 2.7 %, nausea 21.3 %, vomiting 13.2 %. N=1,298 randomised 2:2:1; primary endpoint HbA1c non-inferiority of 12 mg; HbA1c superiority of 9 mg nominal only. Topline release; publication pending.
Verbatim quotes from the source (10)
- retatrutide 9 mg · weight_eff · Results, paragraph 2 and efficacy estimand table
Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic.
- retatrutide 9 mg · ae_dc · Results, adverse events paragraph
Treatment discontinuation rates due to adverse events were 4.8%, 7.9% vs. 2.7% with retatrutide 9 mg and 12 mg vs. Ozempic, respectively.
- retatrutide 9 mg · nausea · Results, adverse events paragraph
nausea (21.2%, 23.8% vs. 21.3%)
- retatrutide 9 mg · vomiting · Results, adverse events paragraph
vomiting (10.2%, 15.0% vs. 13.2%)
- retatrutide 9 mg · hba1c · Results, paragraph 2 and efficacy estimand table
both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks.
- retatrutide 12 mg · weight_eff · Results, paragraph 2 and efficacy estimand table
Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic.
- retatrutide 12 mg · ae_dc · Results, adverse events paragraph
Treatment discontinuation rates due to adverse events were 4.8%, 7.9% vs. 2.7% with retatrutide 9 mg and 12 mg vs. Ozempic, respectively.
- retatrutide 12 mg · nausea · Results, adverse events paragraph
nausea (21.2%, 23.8% vs. 21.3%)
- retatrutide 12 mg · vomiting · Results, adverse events paragraph
vomiting (10.2%, 15.0% vs. 13.2%)
- retatrutide 12 mg · hba1c · Results, paragraph 2 and efficacy estimand table
both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks.
Primary sources
- Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial [press release]. Indianapolis (IN): Eli Lilly and Company; 2026 Oct 28. Available from: https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html
- ClinicalTrials.gov NCT06260722
How to cite this page
Medical Adviser's Group. Incretin Atlas: TRANSCEND-T2D-2 (vs semaglutide 2 mg). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/transcend-t2d-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.